{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:22:47Z","timestamp":1788351767967,"version":"build-2803163510"},"reference-count":116,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Clear cell renal cell carcinoma (ccRCC) is a highly immune-evasive malignancy that exhibits limited and often transient responses to immune checkpoint inhibitors (ICIs) and remains a major challenge for emerging cellular immunotherapies, including chimeric antigen receptor (CAR)-T cells. A defining feature of ccRCC, largely driven by von Hippel\u2013Lindau (VHL) deficiency, is persistent activation of the transforming growth factor-\u03b21 (TGF-\u03b21) and hypoxia-inducible factor (HIF) signaling network. Acting as a central immunometabolic regulatory axis, TGF-\u03b21\/HIF promotes angiogenesis, metabolic reprogramming, epigenetic dysregulation, and immune escape through coordinated induction of immunosuppressive mediators, including PD-L1, VEGF, and CTLA-4, resulting in impaired T-cell infiltration, functional exhaustion, and resistance to immunotherapy. Preclinical studies have demonstrated that pharmacologic-dose Seleno-L-methionine (SLM) and its active metabolite, methylseleninic acid (MSA), suppress TGF-\u03b21 and both HIF-1\u03b1 and HIF-2\u03b1, leading to downregulation of multiple downstream immunosuppressive pathways at pharmacologically achievable, non-toxic concentrations. In addition to enhancing the antitumor activity of chemotherapy and VEGF-targeted agents, accumulating evidence suggests that SLM exerts broad immunologic, metabolic, and epigenetic effects that may overcome key mechanisms of therapeutic resistance. This review synthesizes current mechanistic and translational evidence supporting the repurposing of SLM as a first-in-class pleiotropic immunomodulatory agent. Using ccRCC as a model of TGF-\u03b21\/HIF-driven immune resistance, we discuss how simultaneous targeting of this central regulatory axis may restore immune surveillance, improve T-cell fitness and trafficking, enhance responses to ICIs and CAR-T cell therapy, and provide a mechanistically rational strategy for the treatment of advanced solid tumors.<\/jats:p>","DOI":"10.3390\/ijms27177858","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:04:16Z","timestamp":1788350656000},"page":"7858","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repurposing Seleno-L-Methionine as a Pleiotropic Immunomodulatory Agent to Overcome TGF-\u03b21\/HIF-Driven Immune Evasion in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Translational Therapeutic Opportunities"],"prefix":"10.3390","volume":"27","author":[{"given":"Youcef M.","family":"Rustum","sequence":"first","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, 666 ELM Street, Buffalo, NY 14202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: Extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Buonerba, C., Dolce, P., Iaccarino, S., Scafuri, L., Verde, A., Costabile, F., Pagliuca, M., Morra, R., Riccio, V., and Ribera, D. (2020). Outcomes associated with first-line anti-PD-1\/PD-L1 agents vs. sunitinib in patients with sarcomatoid renal cell carcinoma: A systematic review and meta-analysis. Cancers, 12.","DOI":"10.3390\/cancers12020408"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.eururo.2021.10.001","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma with sarcomatoid features: A post hoc analysis of CheckMate 214 with extended follow-up","volume":"81","author":"Albiges","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"\u00c1lvarez-Gonz\u00e1lez, E., and Sierra, L.M. (2024). Tricarboxylic Acid Cycle Relationships with Non-Metabolic Processes: A Short Story with DNA Repair and Its Consequences on Cancer Therapy Resistance. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25169054"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41581-019-0210-z","article-title":"Oncometabolites in renal cancer: Warburg\u2019s hypothesis re-examined","volume":"16","author":"Yong","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2106947118","DOI":"10.1073\/pnas.2106947118","article-title":"Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer","volume":"118","author":"Aggarwal","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Fang, Z., Sun, Q., Yang, H., and Zhang, J. (2021). SDHB Suppresses the Tumorigenesis and Development of ccRCC by Inhibiting Glycolysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.639408"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1038\/s41467-025-59513-8","article-title":"Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41419-021-03505-1","article-title":"The crosstalk between HIFs and mitochondrial dysfunctions in cancer development","volume":"12","author":"Bao","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e148438","DOI":"10.1172\/jci.insight.148438","article-title":"The TGF-\u03b2\/HDAC7 axis suppresses TCA cycle metabolism in renal cancer","volume":"6","author":"Nam","year":"2021","journal-title":"JCI Insight"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhu, X., Jiang, L., Long, M., Wei, X., Hou, Y., and Du, Y. (2021). Metabolic Reprogramming and Renal Fibrosis. Front. Med., 8.","DOI":"10.3389\/fmed.2021.746920"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"19287","DOI":"10.1074\/jbc.M116.723080","article-title":"Transforming Growth Factor-\u03b2Increases DNA Methyltransferase 1 and 3a Expression through Distinct Post-transcriptional Mechanisms in Lung Fibroblasts","volume":"291","author":"Koh","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-024-01772-w","article-title":"Targeting carnitine palmitoyl transferase 1A (CPT1A) induces ferroptosis and synergizes with immunotherapy in lung cancer","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_14","first-page":"e2302878120","article-title":"CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing","volume":"120","author":"Liu","year":"2023","journal-title":"Immunother. Inflamm."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yang, J., Miao, D., Li, X., Zhao, C., Tan, D., Wu, S., Lu, F., Shi, J., Lv, Q., and Ruan, H. (2025). Emerging roles of metabolic biomarkers in renal cell carcinoma: From molecular mechanisms to clinical implications. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1664292"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41420-025-02479-9","article-title":"The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma","volume":"11","author":"Zhang","year":"2025","journal-title":"Cell Death Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41467-021-21068-9","article-title":"Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma","volume":"12","author":"Bakouny","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/1078-0432.CCR-20-2063","article-title":"Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"27","author":"Tannir","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00345-018-2447-8","article-title":"WHO\/ISUP classification, grading and pathological staging of renal cell carcinoma: Standards and controversies","volume":"36","author":"Warren","year":"2018","journal-title":"World J. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41585-020-00382-9","article-title":"Sarcomatoid renal cell carcinoma: Biology, natural history and management","volume":"17","author":"Blum","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00432-016-2304-3","article-title":"Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma","volume":"143","author":"Gu","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_22","first-page":"e58470","article-title":"The WHO 2022 Classification of Renal Neoplasms (5th Edition): Salient Updates","volume":"16","author":"Goswami","year":"2024","journal-title":"Cureus"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/PAI.0000000000000561","article-title":"PAXExpression in Solitary Fibrous Tumor: A Potential Diagnostic Pitfall","volume":"27","author":"Ullman","year":"2019","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2013). Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature, 499, 43\u201349.","DOI":"10.1038\/nature12222"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.21037\/tcr.2016.07.30","article-title":"Sarcomatoid renal cell carcinoma: Genomic insights from sequencing of matched sarcomatous and carcinomatous components","volume":"5","author":"Manley","year":"2016","journal-title":"Transl. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1158\/1078-0432.CCR-17-1057","article-title":"Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Xu, W., Anwaier, A., Liu, W., Wei, G., Su, J., Tian, X., Xia, J., Qu, Y., Zhao, J., and Zhang, H. (2022). Genomic alteration of MTAP\/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.953721"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.21873\/anticanres.15271","article-title":"PD-L1 expression and clinicopathological factors in renal cell carcinoma: A comparison of antibody clone 73-10 with clone 28-8","volume":"41","author":"Ikeda","year":"2021","journal-title":"Anticancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/2326-6066.CIR-15-0150","article-title":"PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation","volume":"3","author":"Joseph","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lasorsa, F., di Meo, N.A., Rutigliano, M., Milella, M., Ferro, M., Pandolfo, S.D., Crocetto, F., Tataru, O.S., Autorino, R., and Battaglia, M. (2023). Immune checkpoint inhibitors in renal cell carcinoma: Molecular basis and rationale for their use in clinical practice. Biomedicines, 11.","DOI":"10.3390\/biomedicines11041071"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13046-021-01961-3","article-title":"Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma","volume":"40","author":"Sharma","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Tung, I., and Sahu, A. (2021). Immune checkpoint inhibitor in first-line treatment of metastatic renal cell carcinoma: A review of current evidence and future directions. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.707214"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Czyzyk-Krzeska, M.F., Figueroa, J.A.L., Gulati, S., Cunningham, J.T., Meller, J., Shamsael, B., Vemuri, B., and Plas, D.R. (2021). Molecular and metabolic subtypes in sporadic and inherited clear cell renal cell carcinoma. Genes, 12.","DOI":"10.3390\/genes12030388"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.tibs.2014.06.005","article-title":"The pentose phosphate pathway and cancer","volume":"39","author":"Patra","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Qiao, J., Yu, Z., Zhou, H., Wang, W., Wu, H., and Ye, J. (2025). The pentose phosphate pathway: From mechanisms to implications for gastrointestinal cancers. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26020610"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1073\/pnas.1525735113","article-title":"Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma","volume":"113","author":"Bi","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Cinque, A., Minnei, R., Floris, M., and Trevisani, F. (2022). The clinical and molecular features in the VHL renal cancers; close or distant relatives with sporadic clear cell renal cell carcinoma?. Cancers, 14.","DOI":"10.3390\/cancers14215352"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s12291-017-0713-y","article-title":"Renal cell carcinoma: Molecular aspects","volume":"33","author":"Kumar","year":"2016","journal-title":"Indian J. Clin. Biochem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11934-026-01325-4","article-title":"Sarcomatoid renal cell carcinoma: Biological features and therapeutic implications\u2014A narrative review","volume":"27","author":"Lasorsa","year":"2026","journal-title":"Curr. Urol. Rep."},{"key":"ref_40","first-page":"61","article-title":"Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression","volume":"13","author":"Dogan","year":"2018","journal-title":"Diagn. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Conway, J.W., Braden, J., Wilmott, J.S., Scolyer, R.A., Long, G.V., and Pires da Silva, I. (2022). The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1030147"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1038\/s41598-025-33198-x","article-title":"Comparative efficacy of immune checkpoint inhibitor combination therapies by metastatic site in metastatic renal cell carcinoma","volume":"16","author":"Toyoda","year":"2026","journal-title":"Sci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Rao, Y., Zhang, J.J., Gu, X., Han, J.J., and Ye, Z. (2026). Efficacy and safety of immune checkpoint inhibitors combined with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A risk-stratified systematic review and meta-analysis. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1805039"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0302-2838(02)00400-1","article-title":"Trace elements distribution in renal cell carcinoma depending on stage of disease","volume":"42","author":"Dobrowolski","year":"2002","journal-title":"Eur. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/jn\/137.5.1132","article-title":"Dietary selenium affects homocysteine metabolism differently in liver and lung","volume":"137","author":"Uthus","year":"2007","journal-title":"J. Nutr."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/s41467-017-01965-8","article-title":"HIF drives lipid deposition and cancer in clear-cell renal cell carcinoma via repression of fatty-acid metabolism","volume":"8","author":"Du","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41585-022-00654-6","article-title":"Fatty acid metabolism reprogramming in ccRCC: Mechanisms and potential targets","volume":"20","author":"Tan","year":"2022","journal-title":"Nat. Rev. Urol."},{"key":"ref_48","first-page":"9493256","article-title":"Identification of CPT1A as a prognostic biomarker and potential therapeutic target for kidney renal clear cell carcinoma and establishment of a risk signature of CPT1A-related genes","volume":"2020","author":"Xu","year":"2020","journal-title":"Int. J. Genom."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3724\/abbs.2021023","article-title":"Overexpression CPT1A reduces lipid accumulation via PPAR\u03b1\/CD36 axis to suppress the cell proliferation in ccRCC","volume":"54","author":"Yang","year":"2022","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_50","first-page":"1931","article-title":"Overexpression of PLIN2 is a prognostic marker and attenuates tumor progression in clear cell renal cell carcinoma","volume":"52","author":"Cao","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41419-024-06627-4","article-title":"TRIB3 promotes the progression of renal cell carcinoma by upregulating the lipid droplet-associated protein PLIN2","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Zhan, M., Zhao, B., Chen, H., Wu, J., Shi, R., Gao, F., Zhao, L., and Zhu, J. (2026). Metabolic reprogramming in clear cell renal cell carcinoma: Core pathways and targeted therapeutic strategies. Front. Genet., 16.","DOI":"10.3389\/fgene.2025.1752384"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Roviello, G., De Gennaro, I., Vascotto, I., Venturi, G., D\u2019Angelo, A., Winchler, C., Guarino, A., Cacioppo, S., Modesti, M., and Mela, M.M. (2024). Hypoxia-inducible factor in renal cell carcinoma: From molecular insights to targeted therapies. Genes, 16.","DOI":"10.3390\/genes16010006"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.bbrc.2019.07.121","article-title":"CPT1a downregulation protects against cholesterol-induced fibrosis in tubular epithelial cells by downregulating TGF\u03b2-1 and inflammasome","volume":"517","author":"Calle","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12943-025-02457-w","article-title":"Lipid reprogramming and ferroptosis crosstalk in clear cell renal cell carcinoma: Metabolic vulnerabilities and therapeutic targeting","volume":"24","author":"Deng","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e16079","DOI":"10.1016\/j.heliyon.2023.e16079","article-title":"MiR-210 regulates lung adenocarcinoma by targeting HIF-1\u03b1","volume":"9","author":"Cao","year":"2023","journal-title":"Heliyon"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1186\/s12967-025-06718-6","article-title":"Innovative approaches to CAR-T cell therapy: The role of lipid metabolism pathways","volume":"23","author":"Guo","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"eabq3016","DOI":"10.1126\/sciimmunol.abq3016","article-title":"Metabolic challenges and interventions in CAR T cell therapy","volume":"8","author":"Peng","year":"2023","journal-title":"Sci. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Ghebremedhin, A., Athavale, D., Zhang, Y., Yao, X., Balch, C., and Song, S. (2024). Tumor-Associated Macrophages as Major Immunosuppressive Cells in the Tumor Microenvironment. Cancers, 16.","DOI":"10.3390\/cancers16193410"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41417-025-00886-9","article-title":"MDSC checkpoint blockade therapy: A new breakthrough point overcoming immunosuppression in cancer immunotherapy","volume":"32","author":"Ibrahim","year":"2025","journal-title":"Cancer Gene Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"914","DOI":"10.4161\/cbt.20843","article-title":"Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells","volume":"13","author":"Wonganan","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"(2013). Bostr\u00f6m, A.-K.; Lindgren, D.; Johansson, M.; Axelson, M. Effects of TGF-\u03b2 signaling in Clear Cell Renal Cell Carcinoma cells. Biochem. Biophys. Res. Commun., 435, 126\u2013133.","DOI":"10.1016\/j.bbrc.2013.04.054"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1158\/0008-5472.CAN-13-0992","article-title":"A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells","volume":"74","author":"Barsoum","year":"2014","journal-title":"Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"B\u00e9vant, K., Desoteux, M., Abdel Wahab, A.H.A., Abdel Wahab, S.A., Metwally, A.M., and Coulouarn, C. (2021). DNA Methylation of TGF\u03b2 Target Genes: Epigenetic Control of TGF\u03b2 Functional Duality in Liver Cancer. Cells, 10.","DOI":"10.3390\/cells10092207"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41698-025-01003-7","article-title":"Epigenetic regulators in cancer therapy and progression","volume":"9","author":"Marei","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1101\/gad.276568.115","article-title":"Role of TET enzymes in DNA methylation, development, and cancer","volume":"30","author":"Rasmussen","year":"2016","journal-title":"Genes Dev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e13526","DOI":"10.1111\/acel.13526","article-title":"Inhibition of DNA methyltransferase aberrations reinstate antioxidant aging suppressors and ameliorates renal aging","volume":"21","author":"Gao","year":"2022","journal-title":"Aging Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12929-025-01186-y","article-title":"TCA cycle-derived oncometabolites in cancer and the immune microenvironment","volume":"32","author":"Sarkar","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"100671","DOI":"10.1016\/j.medj.2025.100671","article-title":"CD70-targeted cancer theranostics: Progress and challenges","volume":"6","author":"Wei","year":"2025","journal-title":"Med"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41419-025-07432-3","article-title":"HIF2\u03b1 drives ccRCC metastasis through transcriptional activation of methylation-controlled J protein and enhanced prolegumain secretion","volume":"16","author":"Shen","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"19123","DOI":"10.18632\/oncotarget.24919","article-title":"Hypoxia-inducible factor-2 alpha up-regulates CD70 under hypoxia and enhances anchorage-independent growth and aggressiveness in cancer cells","volume":"9","author":"Kitajima","year":"2018","journal-title":"Oncotarget"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1038\/s41467-020-17873-3","article-title":"HIF-1\u03b1 and HIF-2\u03b1 differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice","volume":"11","author":"Hoefflin","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/abbs\/gmt141","article-title":"Emerging roles of miR-210 and other non-coding RNAs in the hypoxic response","volume":"46","author":"Huang","year":"2014","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.3390\/ijms16036353","article-title":"The role of hypoxia-induced miR-210 in cancer progression","volume":"16","author":"Dang","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"872","DOI":"10.18632\/oncotarget.1825","article-title":"miR-34: From bench to bedside","volume":"5","author":"Agostini","year":"2014","journal-title":"Oncotarget"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Guo, J., Zhao, P., Liu, Z., Li, Z., Yuan, Y., Zhang, X., Yu, Z., Fang, J., and Xiao, K. (2019). MiR-204-3p Inhibited the Proliferation of Bladder Cancer Cells via Modulating Lactate Dehydrogenase-Mediated Glycolysis. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01242"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e15155","DOI":"10.1016\/j.heliyon.2023.e15155","article-title":"p53\/MicroRNA-34 axis in cancer and beyond","volume":"9","author":"Pan","year":"2023","journal-title":"Heliyon"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"CT002","DOI":"10.1158\/1538-7445.AM2024-CT002","article-title":"CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Long-term follow-up and translational data from the phase 1 COBALT-RCC study","volume":"84","author":"Pal","year":"2024","journal-title":"Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"34341","DOI":"10.18632\/oncotarget.9114","article-title":"Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model","volume":"7","author":"Suarez","year":"2016","journal-title":"Oncotarget"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12943-024-01952-w","article-title":"Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Lin, Y., Luo, S., Wei, J., Lin, S., Wang, D., Zhao, X., Feng, Z., Shen, Y., and Chen, Q. (2025). Limitations of CAR-T-Cell Therapy in Hematologic Malignancies: Focusing on Antigen Escape and T-Cell Dysfunction. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26199669"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Haslauer, T., Greil, R., Zaborsky, N., and Geisberger, R. (2021). CAR T-Cell therapy in hematological malignancies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168996"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Bl\u00fcm, P., and Kayser, S. (2024). Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitation. Cancers, 16.","DOI":"10.3390\/cancers16081599"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12943-024-02059-y","article-title":"PD1\/PD-L1 blockade in clear cell renal cell carcinoma: Mechanistic insights, clinical efficacy, and future perspectives","volume":"23","author":"Zhu","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Garcia-Robledo, J.E., Cabrera-Salcedo, S., Brandauer, A.M., Romano, F., Rengifo-Martinez, J., Toro-Pedroza, A., Victoria, J.S., Rios-Serna, L.J., Loukanov, A., and Cardona, A.F. (2026). Engineering the next generation of CAR T-cells: Precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1698442"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/1078-0432.CCR-14-1425","article-title":"pVHL\/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma","volume":"21","author":"Ruf","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Al Shaer, N.S.H., Masoud, I., Tleyjeh, A., Al-Attas, A.A., Al-Attas, M.A., Khan, M.I., and Yaqinuddin, A. (2026). CAR-T cells in solid tumors: Engineering, biomarkers, translational pathways and the road ahead. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1796675"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1200\/JCO.2022.40.6_suppl.384","article-title":"CD70 is a promising CAR-T cell target in patients with advanced renal cell carcinoma","volume":"40","author":"Ye","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","article-title":"Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors","volume":"24","author":"Chen","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","article-title":"Optimizing CAR-T cell therapy for solid tumors: Current challenges and potential strategies","volume":"17","author":"Ai","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.clgc.2023.12.003","article-title":"CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma","volume":"22","author":"Huang","year":"2024","journal-title":"Clin. Genitourin. Cancer."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Rojas-Quintero, J., D\u00edaz, M.P., Palmar, J., Galan-Freyle, N.J., Morillo, V., Escalona, D., Gonz\u00e1lez-Torres, H.J., Torres, W., Navarro-Quiroz, E., and Rivera-Porras, D. (2024). Car T Cells in Solid Tumors: Overcoming Obstacles. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25084170"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Wattling, M.C., Cole, A.C., Brammer, B., Diatikar, K.G., Schmitt, N.C., and Paulos, C.M. (2024). Strategies for Improving CAR T Cell Persistence in Solid Tumors. Cancers, 16.","DOI":"10.3390\/cancers16162858"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Rizkallah, J. (2026). Adoptive cell therapies in solid tumors: Current clinical landscape, challenges, and future directions. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1800292"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41577-025-01229-3","article-title":"Microenvironmental regulation of solid tumour resistance to CAR T cell therapy","volume":"26","author":"Lamplugh","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1093\/carcin\/bgn179","article-title":"Selenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cells","volume":"29","author":"Xiang","year":"2008","journal-title":"Carcinogenesis"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.freeradbiomed.2018.06.002","article-title":"Selenium at the redox interface of the genome, metabolome and exposome","volume":"127","author":"Fernandes","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/15592294.2015.1013792","article-title":"Epigenetic effects of selenium and their implications for health","volume":"10","author":"Speckmann","year":"2015","journal-title":"Epigenetics"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/jn\/132.2.292","article-title":"Dietary selenite and azadeoxycytidine treatments affect dimethylhydrazine-induced aberrant crypt formation in rat colon and DNA methylation in HT-29 cells","volume":"132","author":"Davis","year":"2002","journal-title":"J. Nutr."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Hu, Y., McIntosh, G.H., Le Leu, R.K., Nyskohus, L.S., Woodman, R.J., and Young, G.P. (2013). Combination of selenium and green tea improves the efficacy of chemoprevention in a rat colorectal cancer model by modulating genetic and epigenetic biomarkers. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0064362"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1158\/1078-0432.CCR-24-3234","article-title":"Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Previously Treated Metastatic Clear Cell Renal Cell Carcinoma Patients","volume":"31","author":"Zakharia","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"10765","DOI":"10.18632\/oncotarget.24297","article-title":"Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: Preclinical and clinical development Review","volume":"9","author":"Zakharia","year":"2018","journal-title":"Oncotarget"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Rataan, A.O., Geary, S.M., Zakharia y Rustum, Y.M., and Aliasger, S. (2022). Potential Role of Selenium in the Treatment of Cancer and Viral Infections. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23042215"},{"key":"ref_107","first-page":"100864","article-title":"Targeting transforming growth factor-beta 1 by methylseleninic acid\/seleno-L-methionine in clear cell renal cell carcinoma: Mechanisms and therapeutic potential","volume":"42","author":"Rataan","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00280-009-1238-8","article-title":"Se-methylselenocysteine sensitizes hypoxic tumor cells by targeting hypoxia inducible factor1\u03b1","volume":"66","author":"Chintala","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Chintala, S., Najrana, T., Toth, K., Cao, S., Durrani, F.A., Pili, R., and Rustum, Y.M. (2012). Prolyl hydroxylase Dependent and Von-Hippel-Lindau Independent Degradation of Hypoxia-Inducible Factor 1 and 2 alpha by SeleniuminClear Cell Renal Cell Carcinoma leads to Tumor Growth Inhibition. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-293"},{"key":"ref_110","first-page":"7688","article-title":"Pharmacologic doses of ascorbic acid and seleno-L-methionine are new and novel class of transforming growth factor-beta 1 inhibitor: Mechanisms and therapeutic potential","volume":"14","author":"Rustum","year":"2026","journal-title":"Med. Res. Arch."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1158\/1078-0432.CCR-08-0212","article-title":"Tumor vascular maturation and improved drug delivery induced by Methylselenocysteine leads to therapeutic synergy with anticancer drugs","volume":"14","author":"Bhattacharya","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.canlet.2011.07.023","article-title":"Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation","volume":"311","author":"Azrak","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/bjc.2014.85","article-title":"Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumor activity of anticancer drugs in preclinical animal models","volume":"110","author":"Cao","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_114","first-page":"77","article-title":"Mechanism-based drug combination targeting HIF2\u03b1 and VEGF in renal cancer xenografts","volume":"10","author":"Durrani","year":"2015","journal-title":"Trends Cell Mol. Biol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"6496","DOI":"10.1158\/1538-7445.AM2026-6496","article-title":"Methylseleninic acid enhances anti-FNCAR-T cell effector function and redirects cytotoxicity against TGF-\u03b2\u2013rich kidney, prostate, and brain tumors","volume":"86","author":"Kim","year":"2026","journal-title":"Cancer Res."},{"key":"ref_116","first-page":"C010","article-title":"Anti-FNCAR-T cells overcome TGF-\u03b2\u2013mediated suppression, and their synergy with methylseleninic acid enhances cytotoxicity and effector function in kidney, prostate, and brain tumors","volume":"14","author":"Amissah","year":"2026","journal-title":"AACR-IO"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7858\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:05:50Z","timestamp":1788350750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":116,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27177858"],"URL":"https:\/\/doi.org\/10.3390\/ijms27177858","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}